Track market-moving stories before they get noisy

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV - Free Report) or Revvity (RVTY - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Elevance Health has a Zacks Rank of #2 (Buy), while Revvity has a Zacks Rank of #3 (Hold) right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ELV is likely seeing its earnings outlook improve to a greater extent. But this is just one factor that value investors are interested in.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

ELV currently has a forward P/E ratio of 16.37, while RVTY has a forward P/E of 29.35. We also note that ELV has a PEG ratio of 2.32. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. RVTY currently has a PEG ratio of 2.86.

Another notable valuation metric for ELV is its P/B ratio of 2.15. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, RVTY has a P/B of 2.43.

Based on these metrics and many more, ELV holds a Value grade of A, while RVTY has a Value grade of C.

ELV sticks out from RVTY in both our Zacks Rank and Style Scores models, so value investors will likely feel that ELV is the better option right now.

Revvity is transforming from a legacy tools company into a diagnostics-driven, AI-enabled platform with robust double-digit diagnostics growth. The Diagnostics segment organic revenue rose 11%, while software ARR grew in the mid-20% range, offsetting Life Sciences weakness and China exit headwinds. Operating leverage is strong, with 13% EPS growth on 3% organic revenue growth and free cash flow conversion exceeding 100%, supporting deleveraging and strategic reinvestment.

Danaher (DHR), one of the world’s largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027.

While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation. By uniting key subsidiaries like Beckman Coulter and Abcam into a single connected workflow, the company is building an automated biological assembly line.

Key Takeaways The Physical Lab Bottleneck: While AI can design prospective drug molecules in seconds, validating whether they work still depends on slow physical wet-lab testing and custom testing tools. Danaher’s Automation Play: Scheduled to launch at commercial scale in early 2027, Danaher’s autonomous lab aims to produce essential testing tools up to 8x faster, breaking a major preclinical roadblock for drug developers. A Picks-and-Shovels Investment: Because roughly 90% of experimental drugs fail in human trials, investing in laboratory automation and consumable providers offers exposure to the AI drug discovery boom without the risk of speculative biotech pipelines. The Assembly Line Bottleneck in Drug Discovery For advisors interested in investing in AI drug discovery, the most useful parallel is semiconductor manufacturing. Software tools can design complex microchips on a screen, but those designs are useless without semiconductor fabs to physically manufacture and subsequently test them.

Biopharma faces that exact reality today. AI models can now easily generate promising therapeutic drug candidates. However, testing whether those digital blueprints actually work still requires labor-intensive manual experimentation and liquid handling across separate equipment stations. In other words, physical wet-lab testing remains the primary bottleneck that stalls drug development. 

Autonomous laboratories eliminate this friction by replacing manual benchwork with an interconnected, 24/7 robotic assembly line. It itests and validates AI-generated molecules without human downtime. One framework for solving this bottleneck is the Design-Make-Test-Learn (DMTL) cycle. 

Operating as a continuous feedback loop, algorithms design new molecular candidates, automated lab equipment physically synthesizes and tests them, and the resulting biological data feeds directly back into the models. Each iteration provides new data to refine the software’s predictions for the next batch of molecules.

In practice, very few companies own the complete technology stack required to run this entire loop in-house. Most drug developers must assemble a patchwork of specialized software, robotic hardware, and testing instruments from multiple independent vendors.

The Key Companies Powering the Automated Biological Factory Lab automation which covers the “make” and “test” part of the loop works like an advanced manufacturing plant.  There are specialized machines that handle the distinct steps along the line. 

The assembly line begins with physical raw materials. A computer model cannot validate a digital blueprint until a company like Twist Bioscience (TWST) prints the physical DNA. Twist acts as the factory’s biological printer, using silicon chips to produce custom genetic code at scale.

Next, robots take over the factory floor. Instead of human operators, automated liquid handlers from industry leaders, such as those from Tecan Group (TCHBF), measure and mix chemical compounds, guided by software that receives instructions from computational models.

To transport those samples through the facility, Thermo Fisher (TMO) supplies robotic transport arms and enterprise scheduling software. Meanwhile, high-speed imaging instruments from Revvity (RVTY) photograph cellular reactions in real time to monitor biological behavior. Many of these systems will likely be made using critical components manufactured by Novanta (NOVT), the leading OEM supplier for the industry for precision motion and imaging. 

Investing in key enablers of AI-powered labs can be complex. The ROBO Global Healthcare Technology and Innovation Index (HTEC) simplifies this by providing broad exposure across targeted subsegments such as Process Automation, Diagnostics, and Genomics.

Danaher Automates the Essential Tools of Drug Discovery AI models can design promising new drug candidates in seconds. However, testing whether those designs actually work requires specialized biological tools known as affinity reagents. These custom molecular probes act like sensors, allowing scientists to confirm whether a drug hits its target.

Producing these testing tools traditionally relies on slow, animal-based methods that take months. This creates a major bottleneck, leaving researchers waiting for the physical tools required to validate their digital blueprints.

Danaher’s autonomous lab directly targets this delay. Scheduled to operate at commercial scale in early 2027, the facility combines automated robotics, testing supplies, and software under one roof to run the entire discovery loop automatically.

By taking humans off the benchtop, Danaher aims to speed up reagent creation by up to 8x while increasing annual output tenfold.

For drug developers, removing this roadblock allows teams to run tests much faster and weed out failed ideas early. For investors, it offers a classic picks-and-shovels opportunity, capturing value from the growth of AI drug discovery by supplying the essential testing tools the industry cannot run without.

Investing in the Physical Backbone of AI Drug Discovery Danaher’s initiative has the potential to level the playing field across biotech. By automating the production of custom testing tools, smaller research teams can validate disease targets faster. They can also do it without the massive budgets traditionally required for specialized lab work.

Even with automation speeding up early lab testing, real-world biology remains unpredictable. Every drug candidate must still go through years of human clinical trials, where roughly 90% of experimental medicines historically fail. Artificial intelligence can design a molecule in seconds, but it cannot skip the human testing required to prove clinical safety.

For investors, the most reliable way to participate in AI drug discovery is through the infrastructure companies that make testing possible. Equipment and lab supply providers operate on steady, recurring revenue models, generating business regardless of which specific drug succeeds.

The ROBO Global Healthcare Technology and Innovation Index (HTEC) captures this opportunity by targeting the key enablers of modern lab science. By focusing on segments like process automation, genomics, and robotics, the index allows investors to capture the growth of AI drug discovery through physical lab leaders rather than high-risk clinical pipelines.

Related Research The Top HealthTech Questions Landing on Our Desks

Why Moderna’s Cancer Vaccine Matters to Investors

3 Companies Redefining Healthcare Innovation

HTEC is the underlying index for the Robo Global Healthcare Technology & Innovation ETF (HTEC) and the L&G Healthcare Technology & Innovation UCITS ETF (DOCT.LN). 

Looking for regular updates? Subscribe here for weekly insights on Healthcare Technology, AI, and Robotics, delivered straight to your inbox.

For more news, information, and strategy, visit the Disruptive Technology Content Hub.

VettaFi is the index provider for HTEC ETF and DOCT.LN, for which it receives an index licensing fee. However, HTEC ETF and DOCT.LN are not issued, sponsored, endorsed, or sold by VettaFi. VettaFi and its affiliates have no obligation or liability in connection with the issuance, administration, marketing, or trading of  HTEC ETF and DOCT.LN.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.Presentations from members of Revvity's senior management team will provide updates on the Company's key business initiatives, operational achievements and financial outlook.To register for the Investor Day webcast, visit here. A replay of the webcast and all presentations will be available on the Events page of the Revvity Investor Relations webs.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section o.

Key Takeaways Revvity is positioned for growth across diagnostics, life sciences and scientific informatics.Diagnostics organic revenues rose 11% in Q2, led by Reproductive Health and Immunodiagnostics growth.AI-driven demand and the Human Cell Design deal expand Revvity's life sciences and screening capabilities. Revvity, Inc. (RVTY - Free Report) is well-positioned for growth, thanks to its strong product portfolio. The company is positioned for growth across diagnostics, life sciences and scientific informatics. Diagnostics remains a key growth engine, while new screening solutions and the planned Human Cell Design acquisition expand its addressable markets. However, China divestiture uncertainty, uneven academic demand and margin pressure from nonrecurring tariff benefits remain near-term challenges.

This Zacks Rank #3 (Hold) company’s shares rallied 56.1% in the year-to-date period compared with the industry’s 4.8% growth. The S&P 500 jumped 11.8% during the same time frame.

The renowned provider of health science solutions has a market capitalization of $16.86 billion. It projects 10.3% growth over the next five years and expects to witness continued improvement in its business going forward. Revvity’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 6.59%.

Image Source: Zacks Investment Research

Let’s delve deeper.

Upsides of RVTY StockExpanding Markets Through AI and Life Sciences: Revvity’s presence across diagnostics, multi-omics, translational research and scientific informatics provides exposure to healthcare screening and R&D modernization. In the second quarter of 2026, pharma and biotech conditions improved for the third consecutive quarter, while sales to these customers, excluding software, grew in the low single digits. The company also saw direct orders tied to AI-driven data generation from pharma and biotech customers, AI-focused organizations and nonprofits. This trend supports demand for instruments, reagents and software as AI-generated hypotheses require biological data and laboratory validation.

Revvity also strengthened its life sciences portfolio in September by agreeing to acquire Human Cell Design, a France-based developer of human-relevant cell models for metabolic diseases. The deal is expected to expand Revvity’s capabilities in drug discovery, high-content screening and cell analysis, particularly for GLP-1 and other metabolic therapies.

Diagnostics Provides a More Stable Growth Base: Diagnostics continued to deliver stronger growth, with pro forma organic revenues increasing 11% year over year in the second quarter, following 9% growth in the first quarter. Reproductive Health grew in the mid-teens, supported by newborn screening and the Genomics England sequencing contract, while Immunodiagnostics outside China accelerated to the high single digits.

Revvity has strengthened this franchise by launching the SuperFlex prenatal screening system, a CE-IVDR-certified immunoassay platform designed for small and mid-sized laboratories and clinics. The company also launched the GSP T1D 3plex kit, a CE-IVDR-certified solution designed for population-wide screening of children at risk of Type 1 diabetes. The offering extends the company’s newborn-screening capabilities and could broaden its addressable diagnostics market.

Product Innovation Supports the Life Sciences Recovery: Revvity is advancing its product cycle across high-content screening and scientific software. Demand for the Opera Phenix OptIQ remained strong in the second quarter, while instrument backlog reached its highest level in three to four years. Signals AI, the Anthropic connector and other software initiatives are expanding the company’s scientific informatics ecosystem.

The Human Cell Design agreement, expected to close in the fourth quarter of 2026, further complements these capabilities by combining human-relevant cell models with Revvity’s screening, detection and analysis technologies.

Downsides of RevvityChina Divestiture Creates a Transitional Overhang: Revvity has entered into a definitive agreement to divest its China Immunodiagnostics business, which represented about 6% of fiscal 2025 revenues. The transaction is expected to close by the end of 2027 and remains subject to regulatory approvals. Until completion, reported results will continue to include the business, while forward-looking guidance is provided on a pro forma basis excluding it.

Academic Funding Remains Uneven: Life Sciences continues to face exposure to academic and government funding cycles. Sales to these customers declined in the low single digits in the second quarter, partly reflecting software comparisons. Although management expects Life Sciences trends to improve in the second half, a slower recovery in research funding could delay instrument purchases and software renewals.

Margins Remain Sensitive to One-Time Benefits: Pro forma adjusted operating margin was supported by $16 million of tariff-related refunds in the second quarter. Revvity raised full-year pro forma adjusted operating-margin guidance to 28.7%, but the tariff benefit is not recurring. Management plans to reinvest roughly half of the benefit into strategic initiatives, supply chain and personnel, making sustained margin expansion dependent on organic growth, favorable mix and operating efficiency.

Estimate TrendRevvity has been witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has remained unchanged at $5.36.

The Zacks Consensus Estimate for third-quarter 2026 revenues is pegged at $702.6 million, indicating a 0.5% improvement from the year-ago reported number. The Zacks Consensus Estimate for EPS is pinned at $1.28, implying a year-over-year gain of 8.5%.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.

Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.

24.9.2026 22:09

Zámořské akciové trhy během dnešního obchodování kolísaly a nakonec zakončily bez výraznějších změn. Index Dow Jones klesl o 0,31 % na 51 349,98 bodu, širší index S&P 500 odepsal 0,02 % na 7 704,15 bodu a technologický Nasdaq Composite připsal 0,01 % na 26 939,37 bodu. Investoři reagovali na obnovenou volatilitu na dluhopisovém trhu a růst cen ropy, které rozdmýchaly obavy z přetrvávající inflace a dalšího zpřísňování měnové politiky ze strany americké centrální banky.

V rámci indexu S&P 500 se nejvíce dařilo sektorům komunikačních služeb se ziskem 1,9 %, zdravotní péče s růstem o 0,6 % a energií, které přidaly 0,4 %. Naopak nejvýraznější ztráty zaznamenaly základní materiály s poklesem o 1 %, nezbytná spotřeba a utility, které oslabily shodně o 1 %.

Mezi nejziskovější akcie se zařadily společnosti Everpure (P) s růstem o 11 %, Illumina (ILMN) o 7,3 %, Charles River Laboratories International (CRL) o 6,2 %, Moderna (MRNA) o 7,0 % a Revvity (RVTY) o 6,0 %. Nejvýraznější propad naopak postihl akcie MGM Resorts International (MGM), které ztratily 11 % poté, co společnost People Inc. odstoupila od záměru na převzetí zbývajícího podílu v podniku. Dále oslabily společnosti First Solar (FSLR) o 10 %, Gen Digital (GEN) o 12 %, Rollins (ROL) o 6,4 % a Xylem (XYL) o 5,6 %.

Na komoditních trzích vzrostla cena ropy WTI o 2,9 % na 94,83 dolaru za barel a severomořská ropa Brent se usadila nad 106 dolary za barel. Spotové zlato zlevnilo o 0,4 % na 4 269,50 dolaru za unci. Dolarový index posílil o 0,3 %, přičemž euro vůči dolaru zůstalo téměř beze změny na úrovni 1,1375 USD, britská libra klesla o 0,2 % na 1,3216 USD a japonský jen oslabil o 0,4 % na 158,89 JPY za dolar. Výnosy amerických dluhopisů vzrostly, výnos desetiletých dluhopisů stoupl na 5,17 % a výnos třicetiletých dluhopisů dosáhl 5,47 %, což je nejvyšší úroveň od roku 2004.

Daniel Marván
Fio banka, a.s.
Prohlášení

State Street Corp boosted its stake in Revvity Inc. (NYSE:RVTY – Free Report) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,342,739 shares of the company’s stock after acquiring an additional 32,426 shares during the period. State Street Corp owned 3.89% of Revvity worth $483,173,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Revvity during the second quarter worth $3,845,000. Bank of New York Mellon Corp purchased a new position in Revvity during the 2nd quarter worth $78,766,000. Tocqueville Asset Management L.P. purchased a new position in Revvity during the 2nd quarter worth $4,791,000. The Manufacturers Life Insurance Company lifted its stake in shares of Revvity by 5.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company’s stock worth $41,048,000 after acquiring an additional 20,278 shares during the period. Finally, California State Teachers Retirement System lifted its stake in shares of Revvity by 19.8% in the 1st quarter. California State Teachers Retirement System now owns 133,809 shares of the company’s stock worth $11,723,000 after acquiring an additional 22,075 shares during the period. 86.65% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Revvity In other news, insider Maxwell Krakowiak sold 1,631 shares of Revvity stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the transaction, the insider owned 14,781 shares of the company’s stock, valued at $2,136,297.93. The trade was a 9.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Tajinder S. Vohra sold 7,330 shares of Revvity stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the transaction, the insider directly owned 6,635 shares of the company’s stock, valued at $934,738.80. This trade represents a 52.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 9,046 shares of company stock valued at $1,277,685. 0.85% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades A number of research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. KeyCorp raised their price objective on shares of Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Zacks Research raised Revvity from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. UBS Group assumed coverage on Revvity in a research report on Wednesday, September 9th. They set a “neutral” rating and a $140.00 target price on the stock. Finally, Royal Bank Of Canada assumed coverage on Revvity in a research note on Tuesday, September 1st. They set a “sector perform” rating and a $135.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $116.57. Read Our Latest Research Report on RVTY

Revvity Stock Down 0.8% Shares of NYSE RVTY opened at $142.23 on Thursday. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. Revvity Inc. has a 52 week low of $81.22 and a 52 week high of $149.52. The firm has a 50-day moving average price of $122.53 and a 200 day moving average price of $105.76. The stock has a market capitalization of $15.87 billion, a price-to-earnings ratio of 67.73, a price-to-earnings-growth ratio of 2.61 and a beta of 1.09.

Revvity (NYSE:RVTY – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. During the same period in the prior year, the business posted $1.18 earnings per share. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s payout ratio is currently 13.33%.

About Revvity (Free Report)

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.

Read More Five stocks we like better than Revvity Chips to Bots: Qualcomm’s Agentic AI Breakout Ciena Fell 40%—Now One Analyst Sees 50% Upside Energy Transfer Taps the AI Power Boom Viking’s Obesity Edge May Be Staying Power, Not Weight Loss Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY – Free Report).

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.

Revvity (NYSE:RVTY – Get Free Report) and Cytek Biosciences (NASDAQ:CTKB – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Analyst Recommendations This is a summary of current recommendations for Revvity and Cytek Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revvity 0 14 4 0 2.22 Cytek Biosciences 1 2 3 0 2.33 Revvity currently has a consensus price target of $116.57, indicating a potential downside of 20.61%. Cytek Biosciences has a consensus price target of $5.56, indicating a potential upside of 6.77%. Given Cytek Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Cytek Biosciences is more favorable than Revvity.

Profitability This table compares Revvity and Cytek Biosciences’ net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Revvity 8.16% 8.34% 5.01% Cytek Biosciences -38.98% -12.40% -9.17% Valuation & Earnings This table compares Revvity and Cytek Biosciences”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.86 billion 5.74 $241.20 million $2.10 69.92 Cytek Biosciences $201.49 million 3.36 -$66.54 million ($0.62) -8.40 Revvity has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility Revvity has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Insider and Institutional Ownership 86.7% of Revvity shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary Revvity beats Cytek Biosciences on 10 of the 14 factors compared between the two stocks.

About Revvity (Get Free Report)

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

(Get Free Report)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.

Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDT

Company Participants

Stephen Willoughby - Senior VP of Investor Relations & Head of ESG

Conference Call Participants

Robert Bamberger - Robert W. Baird & Co. Incorporated, Research Division

Presentation

Robert Bamberger
Robert W. Baird & Co. Incorporated, Research Division

All right. Great. Good morning, everyone. My name is Robbie Bamberger, Senior Research Analyst covering Life Sciences and Diagnostics. I'm very pleased to be joined this morning by Steve Willoughby, Senior VP of Investor Relations at Revvity. Steve thanks for making the trip.

Stephen Willoughby
Senior VP of Investor Relations & Head of ESG

Yes.

Question-and-Answer Session

Robert Bamberger
Robert W. Baird & Co. Incorporated, Research Division

I guess before we get into segment specifics on the company, would you just mind giving us a quick breakdown, snapshot of the company coming off of Q2 earnings print. What went right in the quarter? And anything you'd like to just point out to investors about the quarter in general?

Stephen Willoughby
Senior VP of Investor Relations & Head of ESG

Sure. So maybe thanks for having me, first of all. Maybe just a quick overview of the company for those who are not familiar. Revvity a couple of years ago was previously known as PerkinElmer. We divested 30% of the company, including the PerkinElmer brand name, rebranded as Revvity in the middle of 2023.

Revvity today is in the life science tools and diagnostics industry. And what I'd like to say is what we do in life science tools and what we do in diagnostics is typically a little bit different than other publicly traded companies. So specialty diagnostics and then on the life science tools side, really focused in preclinical R&D, providing instruments, consumables, software that are used by academic and pharma biotech customers

Amundi lowered its position in Revvity Inc. (NYSE:RVTY – Free Report) by 7.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 159,232 shares of the company’s stock after selling 12,288 shares during the quarter. Amundi owned about 0.14% of Revvity worth $17,716,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RVTY. AQR Capital Management LLC raised its position in Revvity by 5.2% in the first quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock valued at $883,000 after purchasing an additional 420 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Revvity by 6.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock worth $1,246,000 after purchasing an additional 744 shares during the period. Millennium Management LLC grew its holdings in shares of Revvity by 102.0% during the 1st quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock worth $7,343,000 after purchasing an additional 35,048 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Revvity by 45.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock worth $64,232,000 after purchasing an additional 189,871 shares during the last quarter. Finally, Focus Partners Wealth increased its position in shares of Revvity by 13.0% during the 1st quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock worth $744,000 after purchasing an additional 811 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Price Performance RVTY stock opened at $124.46 on Friday. The business has a 50 day moving average price of $117.71 and a 200 day moving average price of $103.21. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The stock has a market cap of $13.89 billion, a price-to-earnings ratio of 59.27, a PEG ratio of 2.20 and a beta of 1.09. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $133.00.

Revvity (NYSE:RVTY – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The business had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same period in the previous year, the business earned $1.18 EPS. The business’s quarterly revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Revvity Inc. will post 5.36 earnings per share for the current fiscal year. Revvity Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s payout ratio is 13.33%.

Analysts Set New Price Targets RVTY has been the subject of several research analyst reports. Sanford C. Bernstein began coverage on shares of Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 target price for the company. Weiss Ratings raised shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. Royal Bank Of Canada initiated coverage on shares of Revvity in a report on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 price objective on the stock. Wolfe Research assumed coverage on shares of Revvity in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, UBS Group initiated coverage on shares of Revvity in a report on Wednesday. They issued a “neutral” rating and a $140.00 target price for the company. Four analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. Based on data from MarketBeat.com, Revvity presently has an average rating of “Hold” and an average price target of $116.57.

View Our Latest Stock Report on Revvity

Revvity Company Profile (Free Report)

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.

See Also Five stocks we like better than Revvity Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model Kroger’s Textbook Entry for Buy-and-Hold Investors AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window Amgen Drops 10% on a Trial It Didn’t Even Run

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Revvity agreed to acquire HCD, adding human cell models for metabolic disease research.HCD's EndoC-BetaH5 model supports studies of beta cell biology in diabetes and obesity.The HCD acquisition is expected to be closed in fourth-quarter 2026, pending approvals. Revvity, Inc. (RVTY - Free Report) recently announced that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company focused on human cell models and preclinical research solutions for metabolic diseases. The acquisition will bring HCD’s human pancreatic beta cell models into Revvity’s Life Sciences portfolio, strengthening its capabilities in drug discovery, screening and preclinical research for metabolic disease therapies, including GLP-1-targeting treatments.

Per management, HCD’s differentiated human cell models complement Revvity’s technologies supporting drug discovery and development. Combining HCD’s cell models with the company’s screening, detection, automation and analysis capabilities is expected to provide more integrated and human-relevant solutions as researchers seek improved approaches to understanding human biology.

RVTY Stock Trend Following the NewsRVTY stock has lost 2.3% since the announcement on Wednesday. Year to date, the stock has gained 25% compared with the industry’s 1.5% growth and the S&P 500’s 10.3% rise.

The acquisition of HCD is expected to strengthen Revvity’s growth prospects by expanding its position in human-relevant life sciences tools and metabolic disease research. The combination of HCD’s specialized cell models with Revvity’s established detection, cell analysis and screening technologies could create opportunities to support next-generation therapies and broaden customer relationships across the research-to-clinic continuum.

RVTY currently has a market capitalization of $13.82 billion.

Image Source: Zacks Investment Research

More on the NewsHCD brings to Revvity its flagship EndoC-βH5 human pancreatic beta cell model, which is designed to help researchers study beta cell biology and function in areas such as diabetes and obesity. The company’s offerings also include specialized media and reagents, preclinical research capabilities, and its proprietary NatLine platform for developing reliable and functionally consistent human cell models.

The acquisition complements Revvity’s detection and cell analysis capabilities, as EndoC-βH5 cells can be paired with Revvity’s HTRF and AlphaLISA assays to measure pharmacological markers such as cAMP and insulin, as well as pHSense technology for receptor internalization studies. The cells may also be used with ATPlite assays to evaluate cell viability and proliferation.

Together with Revvity’s high-content screening platform, these capabilities could enable researchers to generate and interpret complex cellular data. As wet-lab validation gains importance in AI-enabled science, human-relevant cell models can help researchers validate AI-derived findings.

Beyond early-stage drug discovery, HCD’s technology can support regenerative medicine research for Type 1 diabetes and quality-control activities as cell-based therapies advance toward commercialization. The transaction is expected to be closed in the fourth quarter of 2026, subject to customary closing conditions and regulatory approvals.

Factors Working in Favor of the MarketAccording to data provided by Grand View Research, the global cell analysis market is estimated to be valued at $37.3 billion in 2026 and is expected to witness a CAGR of 11.7% through 2033.

Factors like the growing number of drug discovery activities, increasing prevalence of chronic diseases, rising pharmaceutical and biotechnology R&D investments and advancements in cell analysis technologies are supporting the market’s growth. The increasing adoption of high-content screening, single-cell analysis and advanced cellular profiling is also expected to drive demand for sophisticated cell-based research tools.

Other NewsLast month, Revvity launched the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex will initially be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.

RVTY’s Zacks Rank & Key PicksCurrently, RVTY carries a Zacks Rank #3 (Hold).

Some top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Globus Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Key Takeaways Revvity raised 2026 revenue and EPS guidance as Diagnostics organic revenues grew 11% in the second quarter.RVTY trades at 22.9X forward earnings, above its industry, sector, S&P 500 and five-year median benchmarks.Revvity's software revenues fell about 20%, while second-quarter free cash flow reached $183.8 million. Revvity, Inc. (RVTY - Free Report) is entering the second half of 2026 with stronger operating momentum. Raised guidance, double-digit Diagnostics growth and better cash generation have improved the earnings setup.

The counterweight is valuation. RVTY already trades above its industry, sector and market benchmarks, while software and research-funding volatility keep execution risk in view. That mix favors a selective approach rather than treating the improving outlook as an automatic buy signal.

Revvity’s Growth Outlook Has Clearly ImprovedRevvity raised 2026 pro forma revenue guidance to $2.83-$2.86 billion and adjusted earnings guidance to $5.30-$5.40 per share. The company now expects 4%-5% organic growth, up from its prior 3%-4% range.

Diagnostics is doing much of the heavy lifting. Second-quarter pro forma organic revenues rose 11%, with Reproductive Health up in the mid-teens and Immunodiagnostics outside China accelerating to the high single digits. Danaher Corporation (DHR - Free Report) also reported improving Life Sciences conditions in its second quarter, adding a useful industry read on recovering demand.

RVTY Still Trades at a Premium to Key BenchmarksRVTY trades at 22.9X forward 12-month earnings, above the 16.5X Zacks sub-industry multiple, 21.6X sector multiple and 19.9X for the S&P 500. The stock is also above its five-year median of 21.7X.

That premium raises the bar for execution. Medpace Holdings, Inc. (MEDP - Free Report) , a global clinical contract research organization serving biotechnology and pharmaceutical customers, provides another way to track R&D spending trends, but Revvity’s own multiple already assumes investors will reward a sustained recovery.

Image Source: Zacks Investment Research

Revvity’s Software and Funding Risks RemainLife Sciences pro forma organic revenues fell 3% in the second quarter. Software declined about 20% because of contract-renewal timing and difficult comparisons, more than offsetting low-single-digit growth in Life Sciences Solutions.

Academic and government sales also declined in the low single digits. Management expects software to return to strong double-digit growth in the second half, but uneven funding cycles and renewal timing could make that recovery less linear than the headline guidance suggests.

RVTY’s Cash Flow Supports the Portfolio TransitionSecond-quarter free cash flow reached $183.8 million, equal to 117% of adjusted net income. Year-to-date free cash flow totaled $299 million, representing 108% conversion.

Revvity also retired a €500 million note in July. Management expects gross leverage to fall below 3X by year-end, while net leverage was 2.5X at quarter-end. That balance-sheet progress gives the company more flexibility as it reinvests in growth initiatives and works toward the planned China Immunodiagnostics divestiture.

RVTY’s Rank Helps, but Style Scores Urge SelectivityThe improving outlook supports the fundamental case, but valuation and mixed operating trends argue against ignoring entry price. The setup looks stronger than it did earlier in the year, yet the risk-reward remains more balanced than the raised guidance alone might imply.

RVTY currently carries a Zacks Rank #3 (Hold), while the Zacks Consensus Estimate for current-year earnings has risen 2.1% over the past four weeks. That combination points to moderately favorable near-term earnings-estimate momentum. While Medpace carries a Zacks Rank #2 (Buy), Danaher carries a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Style Scores are less supportive. Revvity has a Value Score of D, Growth Score of C, Momentum Score of F and VGM Score of F. Because Style Scores are designed to complement the Zacks Rank, those weaker readings suggest investors may want greater selectivity despite the positive Rank, particularly while the stock trades at a premium valuation.

Bank of New York Mellon Corp purchased a new stake in Revvity Inc. (NYSE:RVTY – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 707,941 shares of the company’s stock, valued at approximately $78,766,000. Bank of New York Mellon Corp owned 0.63% of Revvity as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Ascentis Independent Advisors purchased a new position in shares of Revvity in the first quarter worth approximately $29,000. CYBER HORNET ETFs LLC purchased a new position in Revvity during the 2nd quarter worth approximately $32,000. MUFG Securities EMEA plc purchased a new position in Revvity during the 2nd quarter worth approximately $34,000. SJS Investment Consulting Inc. raised its stake in Revvity by 5,210.0% during the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after purchasing an additional 521 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in Revvity during the 2nd quarter valued at $49,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Trading Up 1.5% NYSE:RVTY opened at $124.79 on Wednesday. The stock’s 50 day moving average price is $112.37 and its 200 day moving average price is $100.63. Revvity Inc. has a 52 week low of $81.22 and a 52 week high of $124.97. The company has a market capitalization of $13.93 billion, a P/E ratio of 59.42, a P/E/G ratio of 2.24 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80.

Revvity (NYSE:RVTY – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same period in the previous year, the firm posted $1.18 earnings per share. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts forecast that Revvity Inc. will post 5.36 EPS for the current fiscal year. Revvity Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a $0.07 dividend. The ex-dividend date is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity’s dividend payout ratio is currently 13.33%.

Analysts Set New Price Targets RVTY has been the subject of several recent analyst reports. Weiss Ratings raised Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Robert W. Baird set a $117.00 price target on Revvity in a research report on Wednesday, May 6th. Zacks Research raised Revvity from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Wall Street Zen lowered Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Finally, Sanford C. Bernstein started coverage on Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $108.36.

Check Out Our Latest Stock Analysis on Revvity

Revvity Profile (Free Report)

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

Featured Stories Five stocks we like better than Revvity Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.

On August 19, 2026, Revvity Inc
RVTY +5.01% 78

shares rose by 5.0% to a current price of $119.45, moving within a 52-week range of $81.22 to $122.11. This upward movement reflects positive sentiment in the market, although it is essential to assess the stock's valuation from a fundamental perspective.

GF Value™ verdict: Current price is $119.45, which is 1.6% overvalued compared to the GF Value™ of $117.56. GF Score™ of 78/100 indicates the stock is above average in terms of overall performance metrics. Most notable signal: Insiders sold $4.7M worth of shares over the past 12 months, without any buying activity. Is RVTY Overvalued or Undervalued? Revvity Inc's current price of $119.45 is slightly above the GF Value™ estimate of $117.56, indicating that the stock is 1.6% overvalued. The GF Value™ is GuruFocus' proprietary estimate of intrinsic value, calculated based on historical trading multiples, past business growth, and future performance expectations. This suggests that while the stock may not be significantly overvalued, there is minimal margin of safety for potential investors.

The GF Valuation label classifies the stock as fairly valued, which aligns with the current price being just above the intrinsic estimate. Investors should proceed with caution, as being slightly overvalued could present risks if market conditions change or if the company does not meet growth expectations.

How Does RVTY's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 56.9x 29.3x Forward P/E 22.3x N/A The current P/E ratio of 56.9x is significantly above the 5-year median of 29.3x, indicating that Revvity Inc is trading at a premium compared to its historical valuation metrics. This P/E analysis corroborates the GF Value™ verdict of the stock being overvalued, as the elevated P/E suggests that investors are paying substantially more for each earnings dollar than they have historically.

What Does RVTY's GF Score™ Tell Us? GF Score™ evaluates a stock based on several critical performance metrics, including financial strength, profitability, growth, valuation, and momentum. Revvity Inc's GF Score™ of 78/100 indicates a strong overall performance, with notable strengths and weaknesses across different sub-ranks.

Metric Rating GF Score™ 78 Financial Strength 6/10 Profitability 7/10 Growth 4/10 Valuation 9/10 Momentum 10/10 The strongest area for Revvity Inc is its momentum rank of 10/10, indicating robust recent performance. Conversely, the growth rank of 4/10 suggests that the company may face challenges in maintaining its growth trajectory. Overall, while the company shows promise in valuation and momentum, it needs to enhance its growth prospects to strengthen its long-term appeal.

What Are Gurus and Insiders Doing with RVTY? Currently, 6 gurus hold shares of Revvity Inc, with 1 adding to their positions and 5 trimming their holdings in recent quarters. This mixed sentiment among gurus may indicate a cautious outlook on the stock's future performance.

Additionally, insider activity shows that insiders sold $4.7M worth of shares over the past 12 months without any buying activity. This trend of selling could suggest a lack of confidence from insiders about the company's near-term prospects, which might be a red flag for potential investors.

What This Means for Investors Based on the GF Value™ assessment, Revvity Inc
RVTY +5.01% 78

is currently overvalued at its price of $119.45 compared to the GF Value™ of $117.56. The lack of margin of safety, elevated P/E ratio, and caution from both gurus and insiders suggest that investors may want to carefully evaluate the risks before entering a position. To explore more about Revvity Inc (RVTY), you can visit the Revvity Inc (RVTY) stock page for a deeper analysis.

Frequently Asked Questions What is RVTY's GF Score™?

RVTY's GF Score™ is 78/100, indicating that the stock performs above average across multiple performance metrics.

Is RVTY overvalued or undervalued?

RVTY is currently overvalued, with a GF Value™ of $117.56 compared to its market price of $119.45.

What is RVTY's P/E ratio?

RVTY's P/E TTM is 56.9x, which is significantly above its 5-year median of 29.3x, indicating a premium valuation compared to its historical performance.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Key Takeaways SuperFlex expands prenatal and preeclampsia testing access for small and mid-sized labs and clinics.Revvity's automated benchtop system runs up to 60 tests per hour, with results in as little as 14 minutes.SuperFlex will launch in CE-marked markets first, with Asia-Pacific expansion planned for late 2026.
Revvity, Inc. (RVTY - Free Report) recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.

Per management, the SuperFlex system represents a significant addition to Revvity’s prenatal screening portfolio by addressing financial and operational barriers associated with in-house testing. The company believes the platform’s accessibility, simplicity and flexible throughput can enable this potentially life-saving testing to be more accessible to women, irrespective of where they receive care.

Likely Trend of RVTY Stock Following the NewsShares of RVTY have gained 1.6% since the announcement on Monday. Year to date, the stock rose 21.8% compared with the industry’s 1.2% growth and the S&P 500’s 12.7% gain.

The launch of SuperFlex is expected to strengthen Revvity’s position in the prenatal screening and reproductive health market. By targeting small and mid-sized laboratories that may not have access to high-throughput centralized testing, the platform could expand the company’s addressable market and support broader adoption of its prenatal screening solutions. Growing demand for preeclampsia screening, along with planned expansion into Asia-Pacific, could create additional opportunities for Revvity to increase instrument placements, consumables demand and recurring revenue over the long term.

RVTY currently has a market capitalization of $12.91 billion.

Image Source: Zacks Investment Research

More on the NewsSuperFlex is a fully automated benchtop immunoanalyzer that uses chemiluminescence immunoassay (CLIA) technology and features a cartridge-based design with 24 sample positions. The system can process up to 60 tests per hour, supports continuous sample loading and delivers initial results in as little as 14 minutes. Its flexible workflow allows laboratories to process samples as needed for both urgent and routine testing.

SuperFlex supports in-house screening for preeclampsia, a condition affecting 2% to 8% of pregnancies, while offering first- and second-trimester biochemical prenatal screening. It offers an accessible solution with lower instrument costs, annual maintenance and no reagent wastage at low sample volumes. The system combines full automation with a user-friendly design that can reduce training requirements and integrates with Revvity’s LifeCycle software.

Revvity’s LifeCycle software is a comprehensive informatics and risk-calculation solution that supports maternal and fetal health screening. Together, SuperFlex and LifeCycle provide a decentralized prenatal screening solution for streamlined risk assessment and LIMS data transfer. By enabling cost-effective, decentralized testing, SuperFlex can help laboratories and clinics bring timely prenatal screening closer to patients.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the global preeclampsia diagnostics market is predicted to be valued at $1.33 billion in 2026 and is expected to witness a CAGR of 3.1% through 2035.

Factors like the rising awareness of maternal health, technological advancements in point-of-care testing, and increasing prenatal screening initiatives are boosting the market’s growth.

Other NewsRevvity recently announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support large-volume clinical laboratories performing latent tuberculosis (TB) testing. The platform is targeted for launch in the second half of 2027.

Revvity recently launched Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research.

RVTY’s Zacks Rank & Key PicksRevvity currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Cardinal Health (CAH - Free Report)  and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, reported a fourth-quarter fiscal 2026 adjusted EPS of $2.91, which beat the Zacks Consensus Estimate by 20.3%. Revenues of $63.67 billion missed the Zacks Consensus Estimate by 2.9%.

CAH has an estimated long-term earnings growth rate of 13.5%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.7%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

[url="]Revvity, Inc.[/url] (NYSE: RVTY), today announced it will present at the following investor conferences:Wells Fargo 21st Annual Healthcare ConferenceWedn

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes an.

Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript

Revvity (RVTY - Free Report) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.18 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +14.63%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.02 per share when it actually produced earnings of $1.06, delivering a surprise of +3.92%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Revvity, which belongs to the Zacks Medical Services industry, posted revenues of $729.69 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.57%. This compares to year-ago revenues of $720.28 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Revvity shares have added about 19.1% since the beginning of the year versus the S&P 500's gain of 11%.

What's Next for Revvity?While Revvity has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Revvity was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.30 on $678.78 million in revenues for the coming quarter and $5.25 on $2.84 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Auna S.A. (AUNA - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 18.

This company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of -27.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Auna S.A.'s revenues are expected to be $350.52 million, up 13.4% from the year-ago quarter.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026.

The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related refunds), as compared to $91 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.2% as a percentage of revenue, as compared to 12.6% in the same period a year ago.

Adjusted earnings per share from continuing operations for the quarter was $1.41, as compared to $1.18 in the same period a year ago. Adjusted operating income was $211 million, as compared to $192 million for the same period a year ago. Adjusted operating profit margin was 28.9% as a percentage of revenue, as compared to 26.6% in the same period a year ago.

Enters into Definitive Agreement to Divest China Immunodiagnostics Business

The Company recently entered into a definitive agreement to divest its Immunodiagnostics business in China (“China IDX”), which represented approximately 6% of the Company’s total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. The Company is providing second quarter 2026 financial results on a reported and pro forma basis; forward-looking guidance is provided on a pro forma basis only and excludes China IDX.

Pro forma earnings per share from continuing operations for the quarter was $0.52, as compared to $0.48 in the same period a year ago. Pro forma revenue for the quarter was $711 million, as compared to $681 million in the same period a year ago. Pro forma operating income was $94 million, as compared to $85 million in the same period a year ago. Pro forma operating profit margin was 13.2% as a percentage of pro forma revenue, as compared to 12.4% in the same period a year ago.

On a pro forma adjusted basis, earnings per share for the quarter was $1.41 (which includes approximately $0.11 from tariff related refunds), as compared to $1.15 in the same period a year ago. Pro forma adjusted operating income was $209 million (which includes $16 million of tariff related refunds), as compared to $180 million for the same period a year ago. Pro forma adjusted operating profit margin was 29.3% as a percentage of pro forma revenue, as compared to 26.5% in the same period a year ago.

Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.

“Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base,” said Prahlad Singh, president and chief executive officer of Revvity. “As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth.”

Financial Overview by Reporting Segment

Life Sciences

Second quarter 2026 revenue was $359 million, as compared to $366 million in the same period a year ago. Pro forma revenue decreased 2% and pro forma organic revenue decreased 3% as compared to the same period a year ago. Second quarter 2026 adjusted operating income was $112 million, as compared to $115 million in the same period a year ago. Adjusted operating profit margin was 31.1% as a percentage of revenue, as compared to 31.6% in the same period a year ago. Diagnostics

Second quarter 2026 revenue was $371 million, as compared to $354 million in the same period a year ago. Pro forma revenue increased 12% and pro forma organic revenue increased 11% as compared to the same period a year ago. Second quarter 2026 adjusted operating income was $113 million, as compared to $89 million in the same period a year ago. Adjusted operating profit margin was 30.4% as a percentage of revenue, as compared to 25.2% in the same period a year ago. Full Year 2026 Guidance

For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted earnings per share of $5.30-$5.40.

Guidance for the full year 2026 for pro forma organic revenue growth and pro forma adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Webcast Information

The Company will discuss its second quarter 2026 results and its outlook for business trends during a webcast on August 4, 2026, at 7:30 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes”, “intends”, “anticipates”, “plans”, “expects”, “estimates”, “projects”, “forecasts”, “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) uncertainties related to the development and use of AI in our product offerings and internal operations; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) our failure to comply with data privacy and information security laws and regulations; (18) regulatory changes; (19) our failure to comply with healthcare industry regulations; (20) economic, political and other risks associated with foreign operations; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) significant fluctuations in our stock price; (24) reduction or elimination of dividends on our common stock; and (25) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Revvity, Inc. and Subsidiaries

CONDENSED CONSOLIDATED INCOME STATEMENTS

  Three Months Ended July 5, 2026

Three Months Ended June 29, 2025

(In thousands, except per share data)

As Reported

Pro Forma

As Reported

Pro Forma

Revenue

$

729,688

$

711,109

$

720,284

$

680,547

Cost of revenue

312,822

302,876

327,728

306,814

Selling, general and administrative expenses

278,576

265,739

248,526

235,812

Research and development expenses

48,974

48,798

53,270

53,270

Operating income from continuing operations

89,316

93,696

90,760

84,651

Interest income

(5,259

)

(5,242

)

(8,345

)

(8,327

)

Interest expense

22,990

22,990

22,937

22,937

Change in fair value of investments

5,251

5,251

1,955

1,955

Other expense, net

2,803

4,003

5,563

4,868

Income from continuing operations, before income taxes

63,531

66,694

68,650

63,218

Provision for income taxes

10,050

8,214

13,428

6,754

Income from continuing operations

53,481

58,480

55,222

56,464

Loss from discontinued operations

(1,661

)

(1,661

)

(1,274

)

(1,274

)

Net income

$

51,820

$

56,819

$

53,948

$

55,190

Diluted earnings per share:

Income from continuing operations

$

0.48

$

0.52

$

0.47

$

0.48

Loss from discontinued operations

(0.01

)

(0.01

)

(0.01

)

(0.01

)

Net income

$

0.47

$

0.51

$

0.46

$

0.47

Weighted average diluted shares of common stock outstanding

111,629

111,629

117,538

117,538

ABOVE PREPARED IN ACCORDANCE WITH GAAP

  Additional supplemental information(1):

(per share, continuing operations)

Three Months Ended July 5, 2026

Three Months Ended June 29, 2025

As Reported

Pro Forma

As Reported

Pro Forma

GAAP EPS from continuing operations

$

0.48

$

0.52

$

0.47

$

0.48

Amortization of intangible assets

0.76

0.70

0.73

0.68

Purchase accounting adjustments

0.02

0.02

0.02

0.02

Acquisition and divestiture-related costs

—

—

0.01

0.01

Transformation costs

(0.01

)

(0.01

)

—

—

Change in fair value of investments

0.05

0.05

0.02

0.02

Significant litigation matters and settlements

—

—

0.01

0.01

Restructuring and other

0.32

0.32

0.10

0.10

Tax on above items

(0.21

)

(0.19

)

(0.16

)

(0.16

)

Adjusted EPS from continuing operations

$

1.41

$

1.41

$

1.18

$

1.15

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries

CONDENSED CONSOLIDATED INCOME STATEMENTS

  Six Months Ended July 5, 2026

Six Months Ended June 29, 2025

(In thousands, except per share data)

As Reported

Pro Forma

As Reported

Pro Forma

Revenue

$

1,440,806

$

1,398,021

$

1,385,046

$

1,309,245

Cost of revenue

636,285

612,042

616,944

578,190

Selling, general and administrative expenses

532,458

505,515

498,245

507,149

Research and development expenses

106,861

106,684

106,867

106,867

Operating income from continuing operations

165,202

173,780

162,990

117,039

Interest income

(11,563

)

(11,535

)

(18,426

)

(18,395

)

Interest expense

47,708

47,708

45,901

45,901

Change in fair value of investments

9,455

9,455

(1,118

)

(1,118

)

Other expense, net

6,079

6,567

15,601

14,296

Income from continuing operations, before income taxes

113,523

121,585

121,032

76,355

Provision for income taxes

19,149

17,814

24,141

23,664

Income from continuing operations

94,374

103,771

96,891

52,691

Loss from discontinued operations

(1,836

)

(1,836

)

(706

)

(706

)

Net income

$

92,538

$

101,935

$

96,185

$

51,985

Diluted earnings per share:

Income from continuing operations

$

0.84

$

0.93

$

0.82

$

0.44

Loss from discontinued operations

(0.02

)

(0.02

)

(0.01

)

(0.01

)

Net income

$

0.82

$

0.91

$

0.81

$

0.43

Weighted average diluted shares of common stock outstanding

111,746

111,746

118,882

118,882

ABOVE PREPARED IN ACCORDANCE WITH GAAP

  Additional supplemental information(1):

(per share, continuing operations)

Six Months Ended July 5, 2026

Six Months Ended June 29, 2025

As Reported

Pro Forma

As Reported

Pro Forma

GAAP EPS from continuing operations

$

0.84

$

0.93

$

0.82

$

0.44

Amortization of intangible assets

1.52

1.41

1.41

1.32

Purchase accounting adjustments

0.02

0.02

0.02

0.02

Acquisition and divestiture-related costs

0.01

0.01

0.03

0.03

Change in fair value of investments

0.08

0.08

(0.01

)

(0.01

)

Loss from probable dispositions

—

—

—

0.29

Significant litigation matters and settlements

—

—

0.10

0.10

Significant environmental matters

—

—

(0.01

)

(0.01

)

Disposition of businesses and assets, net

(0.05

)

(0.05

)

—

—

Mark to market on postretirement benefits

(0.02

)

(0.02

)

0.04

0.04

Restructuring and other

0.41

0.40

0.12

0.12

Tax on above items

(0.36

)

(0.34

)

(0.32

)

(0.23

)

Adjusted EPS from continuing operations

$

2.47

$

2.45

$

2.19

$

2.11

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries

REVENUE AND OPERATING INCOME (LOSS)

  Three Months Ended July 5, 2026

Three Months Ended June 29, 2025

(In thousands, except percentages)

As Reported

Pro Forma

As Reported

Pro Forma

Revenue and adjusted operating income

Revenue

$

729,688

$

711,109

$

720,284

$

680,547

Operating income from continuing operations

$

89,316

$

93,696

$

90,760

$

84,651

OP%

12.2

%

13.2

%

12.6

%

12.4

%

Amortization of intangible assets

84,871

78,383

85,289

79,903

Purchase accounting adjustments

1,866

1,866

2,178

2,178

Acquisition and divestiture-related costs

105

39

1,248

1,248

Transformation costs

(736

)

(736

)

—

—

Significant litigation matters and settlements

79

79

1,124

1,124

Restructuring and other

35,508

35,199

11,203

11,203

Adjusted operating income

$

211,009

$

208,526

$

191,802

$

180,307

OP%

28.9

%

29.3

%

26.6

%

26.5

%

Three Months Ended

July 5,

2026

June 29,

2025

(In thousands, except percentages)

Segment revenue:

Life Sciences

$

358,699

$

365,898

Diagnostics

370,989

354,386

Segment revenue

729,688

720,284

Segment operating income:

Life Sciences

$

111,534

$

115,469

31.1

%

31.6

%

Diagnostics

112,866

89,422

30.4

%

25.2

%

Segment operating income

224,400

204,891

Corporate

(13,391

)

(13,089

)

Adjusted operating income

211,009

191,802

Amortization of intangible assets

(84,871

)

(85,289

)

Purchase accounting adjustments

(1,866

)

(2,178

)

Acquisition and divestiture-related costs

(105

)

(1,248

)

Transformation costs

736

—

Significant litigation matters and settlements

(79

)

(1,124

)

Restructuring and other

(35,508

)

(11,203

)

Reported operating income from continuing operations

$

89,316

$

90,760

REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

  Revvity, Inc. and Subsidiaries

REVENUE AND OPERATING INCOME (LOSS)

  Six Months Ended July 5, 2026

Six Months Ended June 29, 2025

(In thousands, except percentages)

As Reported

Pro Forma

As Reported

Pro Forma

Revenue and adjusted operating income

Revenue

$

1,440,806

$

1,398,021

$

1,385,046

$

1,309,245

Operating income from continuing operations

165,202

173,780

162,990

117,039

OP%

11.5

%

12.4

%

11.8

%

8.9

%

Amortization of intangible assets

169,952

157,092

167,989

157,246

Purchase accounting adjustments

2,007

2,007

2,001

2,001

Acquisition and divestiture-related costs

387

324

3,789

3,789

Disposition of businesses and assets, net

(5,074

)

(5,074

)

—

—

Transformation costs

58

58

—

—

Loss from probable dispositions

—

—

—

34,243

Significant litigation matters and settlements

148

148

11,710

11,710

Significant environmental matters

—

—

(1,208

)

(1,208

)

Restructuring and other

46,183

45,197

14,442

14,442

Adjusted operating income

$

378,863

$

373,532

$

361,713

$

339,262

OP%

26.3

%

26.7

%

26.1

%

25.9

%

Six Months Ended

July 5,

2026

June 29,

2025

(In thousands, except percentages)

Segment revenue:

Life Sciences

$

720,544

$

706,293

Diagnostics

720,262

678,753

Segment revenue

1,440,806

1,385,046

Segment operating income:

Life Sciences

$

215,513

$

221,180

29.9

%

31.3

%

Diagnostics

188,988

163,437

26.2

%

24.1

%

Segment operating income

404,501

384,617

Corporate

(25,638

)

(22,904

)

Adjusted operating income

378,863

361,713

Amortization of intangible assets

(169,952

)

(167,989

)

Purchase accounting adjustments

(2,007

)

(2,001

)

Acquisition and divestiture-related costs

(387

)

(3,789

)

Disposition of businesses and assets, net

5,074

—

Transformation costs

(58

)

—

Significant litigation matters and settlements

(148

)

(11,710

)

Significant environmental matters

—

1,208

Restructuring and other

(46,183

)

(14,442

)

Reported operating income from continuing operations

$

165,202

$

162,990

REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

  Revvity, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

  (In thousands)

July 5,

2026

December 28,

2025

Current assets:

Cash and cash equivalents

$

1,022,943

$

919,860

Accounts receivable, net

709,175

744,671

Inventories, net

378,502

379,497

Other current assets

187,101

195,719

Total current assets

2,297,721

2,239,747

Property, plant and equipment, net

456,251

479,249

Operating lease right-of-use assets, net

150,945

165,439

Intangible assets, net

2,224,001

2,347,003

Goodwill

6,607,802

6,613,493

Other assets, net

309,114

323,480

Total assets

$

12,045,834

$

12,168,411

Current liabilities:

Current portion of long-term debt

$

572,156

$

588,828

Accounts payable

165,740

185,464

Accrued expenses and other current liabilities

538,461

556,954

Total current liabilities

1,276,357

1,331,246

Long-term debt

2,633,094

2,631,236

Long-term liabilities

771,359

807,461

Operating lease liabilities

136,266

148,108

Total liabilities

4,817,076

4,918,051

Total stockholders' equity

7,228,758

7,250,360

Total liabilities and stockholders' equity

$

12,045,834

$

12,168,411

PREPARED IN ACCORDANCE WITH GAAP

  Revvity, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS

  Three Months Ended

Six Months Ended

(In thousands)

July 5,

2026

June 29,

2025

July 5,

2026

June 29,

2025

Operating activities:

Net income

$

51,820

$

53,948

$

92,538

$

96,185

Loss from discontinued operations, net of income taxes

1,661

1,274

1,836

706

Income from continuing operations

53,481

55,222

94,374

96,891

Adjustments to reconcile income from continuing operations to net cash provided by continuing operations:

Stock-based compensation

10,731

10,133

19,446

17,864

Restructuring and other

35,508

11,203

46,183

14,442

Depreciation and amortization

102,039

102,778

207,095

200,200

Change in fair value of contingent consideration

1,626

459

1,527

(166

)

Amortization of deferred debt financing costs and

accretion of discounts

1,301

1,218

2,440

2,320

Change in fair value of investments

5,251

1,955

9,455

(1,118

)

Unrealized foreign exchange loss

86

206

186

140

Gains on disposition of businesses and assets, net

—

—

(5,074

)

—

Changes in assets and liabilities which (used) provided cash:

Accounts receivable, net

(17,631

)

(40,041

)

43,916

(21,901

)

Inventories, net

8,060

11,128

(4,778

)

5,642

Accounts payable

(4,320

)

(5,576

)

(18,064

)

3,278

Accrued expenses and other

(4,189

)

(14,367

)

(78,876

)

(49,177

)

Net cash provided by operating activities of continuing operations

191,943

134,318

317,830

268,415

Net cash used in operating activities of discontinued operations

—

—

(10,657

)

(5,942

)

Net cash provided by operating activities

191,943

134,318

307,173

262,473

Investing activities:

Capital expenditures

(11,073

)

(18,868

)

(30,848

)

(34,850

)

Purchases of investments and notes receivables

(2,506

)

—

(3,561

)

—

Proceeds from investments and notes receivables

6,819

—

7,496

—

Proceeds from dispositions of property, plant and equipment

3,036

—

12,039

—

Proceeds from disposition of businesses and assets

—

—

158

229

Cash paid for acquisitions, net of cash acquired

219

—

(67,061

)

—

Net cash used in investing activities of continuing operations

(3,505

)

(18,868

)

(81,777

)

(34,621

)

Net cash provided by investing activities of discontinued operations

—

9,375

—

18,750

Net cash used in investing activities

(3,505

)

(9,493

)

(81,777

)

(15,871

)

Financing Activities:

Payments of debt financing costs

—

(72

)

—

(2,474

)

Payments on other credit facilities

—

(53

)

—

(103

)

Payments for acquisition-related contingent consideration

(350

)

(161

)

(350

)

(1,978

)

Proceeds from issuance of common stock under stock plans

996

—

6,437

2,632

Purchases of common stock

(15,992

)

(293,907

)

(102,488

)

(447,501

)

Dividends paid

(7,814

)

(8,282

)

(15,654

)

(16,715

)

Net cash used in financing activities

(23,160

)

(302,475

)

(112,055

)

(466,139

)

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

(2,563

)

31,953

(10,190

)

48,075

Net increase (decrease) in cash, cash equivalents, and restricted cash

162,715

(145,697

)

103,151

(171,462

)

Cash, cash equivalents, and restricted cash at beginning of period

861,466

1,138,687

921,030

1,164,452

Cash, cash equivalents, and restricted cash at end of period

$

1,024,181

$

992,990

$

1,024,181

$

992,990

Supplemental disclosure of cash flow information:

Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:

Cash and cash equivalents

$

1,022,943

$

991,849

$

1,022,943

$

991,849

Restricted cash included in other current assets

713

1,141

713

1,141

Restricted cash included in other assets

525

—

525

—

Total cash, cash equivalents and restricted cash

$

1,024,181

$

992,990

$

1,024,181

$

992,990

PREPARED IN ACCORDANCE WITH GAAP

  Revvity, Inc. and Subsidiaries

RECONCILIATION OF FINANCIAL METRICS (1)

  Continuing Operations

Three Months Ended

July 5, 2026

Pro forma organic revenue growth:

Pro forma revenue growth from continuing operations

4%

Less: effect of foreign exchange rates

0%

Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

1%

Pro forma organic revenue growth from continuing operations

3%

Life Sciences

Three Months Ended

July 5, 2026

Pro forma organic revenue growth:

Pro forma revenue growth from continuing operations

-2%

Less: effect of foreign exchange rates

0%

Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

1%

Pro forma organic revenue growth from continuing operations

-3%

Diagnostics

Three Months Ended

July 5, 2026

Pro forma organic revenue growth:

Pro forma revenue growth from continuing operations

12%

Less: effect of foreign exchange rates

1%

Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

0%

Pro forma organic revenue growth from continuing operations

11%

(1) amounts may not sum due to rounding

  Revvity, Inc. and Subsidiaries

RECONCILIATION OF FINANCIAL METRICS (1)

  Continuing Operations

Six Months Ended

July 5, 2026

Pro forma organic revenue growth:

Pro forma revenue growth from continuing operations

7%

Less: effect of foreign exchange rates

2%

Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

1%

Pro forma organic revenue growth from continuing operations

4%

Life Sciences

Six Months Ended

July 5, 2026

Pro forma organic revenue growth:

Pro forma revenue growth from continuing operations

2%

Less: effect of foreign exchange rates

1%

Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

1%

Pro forma organic revenue growth from continuing operations

0%

Diagnostics

Six Months Ended

July 5, 2026

Pro forma organic revenue growth:

Pro forma revenue growth from continuing operations

12%

Less: effect of foreign exchange rates

2%

Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

0%

Pro forma organic revenue growth from continuing operations

10%

(1) amounts may not sum due to rounding

  Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions, divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” or “organic growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions and asset impairments. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of revenue.

We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of revenue.

We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of revenue.

We use the term “adjusted net interest and other expense” to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of investments and debt extinguishment costs.

We use the term “adjusted operating income” to refer to GAAP operating income, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” and “adjusted operating margin” to refer to adjusted operating income as a percentage of revenue.

We use the term “free cash flow” to refer to net cash provided by (used in) operating activities of continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”).

We use the term “adjusted net income” to refer to GAAP income from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

We use the term “adjusted earnings per share from continuing operations,” “adjusted earnings per share,” “adjusted EPS,” or “adjusted EPS from continuing operations” to refer to GAAP earnings per share from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

We use the term “pro forma organic revenue” to refer to organic revenue excluding revenue from probable dispositions. We use the related term “pro forma organic revenue growth”, “pro forma organic revenue growth from continuing operations” or “pro forma organic growth” to refer to the measure of comparing current period pro forma organic revenue with the corresponding period of the prior year.

We use the term “pro forma adjusted gross margin” to refer to adjusted gross margin, excluding gross margin from probable dispositions. We use the related term “pro forma adjusted gross margin percentage” to refer to pro forma adjusted gross margin as a percentage of pro forma revenue.

We use the term “pro forma adjusted SG&A expense” to refer to adjusted SG&A expense, excluding SG&A expense from probable dispositions and gains(losses) on sale of probable dispositions. We use the related term “pro forma adjusted SG&A percentage” to refer to pro forma adjusted SG&A expense as a percentage of pro forma revenue.

We use the term “pro forma adjusted R&D expense” to refer to adjusted R&D expense, excluding R&D expense from probable dispositions. We use the related term “pro forma adjusted R&D percentage” to refer to pro forma adjusted R&D expense as a percentage of pro forma revenue.

We use the term “pro forma adjusted net interest and other expense” to refer to adjusted net interest and other expense, excluding net interest and expense from probable dispositions.

We use the term “pro forma adjusted operating income” to refer to adjusted operating income, excluding operating income from probable dispositions. We use the related terms “pro forma adjusted operating profit percentage,” “pro forma adjusted operating profit margin,” and “pro forma adjusted operating margin” to refer to pro forma adjusted operating income as a percentage of pro forma revenue.

We use the term “pro forma adjusted earnings per share from continuing operations,” “pro forma adjusted earnings per share,” “pro forma adjusted EPS,” or “pro forma adjusted EPS from continuing operations” to refer to adjusted earnings per share from continuing operations, excluding net income from probable dispositions and gains (losses) on sale of probable dispositions.

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred. Debt extinguishment costs—we incur costs and income related to the extinguishment of debt, including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations. Purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets, deferred revenue and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded. Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations. Transformation costs—transformation costs consist of external professional service costs related to transformation initiatives focused on business processes modernization, automation, and implementation of global systems to support the new Revvity Business Model. These costs are determined to be noncapitalizable in accordance with accounting standards. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported. Asset impairments—we incur expenses related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred. Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported. Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure. Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred. Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred. Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported. Impact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period’s foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends. Impact of significant tax events—we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded. Change in fair value of investments—we exclude the impact of changes in the value of investments. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported. The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board’s Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, transformation costs, loss from probable dispositions, significant litigation matters and settlements, significant environmental charges, changes in the fair value of investments, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, and restructuring and other charges is calculated based on operational results and a blended jurisdictional tax rate, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on a blended jurisdictional tax rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fr.

Wall Street expects a year-over-year increase in earnings on lower revenues when Revvity (RVTY - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on August 4, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis maker of scientific instruments is expected to post quarterly earnings of $1.23 per share in its upcoming report, which represents a year-over-year change of +4.2%.

Revenues are expected to be $704.54 million, down 2.2% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Revvity?For Revvity, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that Revvity will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Revvity would post earnings of $1.02 per share when it actually produced earnings of $1.06, delivering a surprise of +3.92%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Revvity doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAmong the stocks in the Zacks Medical Services industry, BrightSpring Health Services, Inc. (BTSG - Free Report) , is soon expected to post earnings of $0.37 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of +68.2%. This quarter's revenue is expected to be $3.65 billion, up 16% from the year-ago quarter.

Over the last 30 days, the consensus EPS estimate for BrightSpring Health Services, Inc. has been revised 2.2% down to the current level. Nevertheless, the company now has an Earnings ESP of -1.35%, reflecting a lower Most Accurate Estimate.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that BrightSpring Health Services, Inc. will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Key Takeaways Revvity is developing T-SPOT A201 for high-volume latent TB testing, targeting a late-2027 launch.The platform can process up to 384 samples in eight hours with 45 seconds of hands-on time per sample.RVTY shares rose 2.4% after the announcement and gained 16.9% year to date, beating key benchmarks. Revvity, Inc. (RVTY - Free Report) recently announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support large-volume clinical laboratories performing latent tuberculosis (TB) testing. Targeted for launch in the second half of 2027, the platform is engineered to deliver the performance advantages of the T-SPOT.TB assay while enabling greater workflow efficiency and scalability for high-throughput testing environments.

Per management, the T-SPOT A201 automation platform marks a significant advancement in expanding access to the benefits of T-SPOT.TB testing for high-volume laboratories. The company believes the solution will provide the performance, workflow efficiency and competitive economics needed by high-volume clinical labs, reinforcing its commitment to delivering scalable automation technologies for infectious disease diagnostics.

Likely Trend of RVTY Stock Following the NewsFollowing the announcement, RVTY shares gained 2.4% at yesterday’s close. Year to date, the stock rose 16.9%, outperforming the industry’s 1.8% decline and the S&P 500’s 7.4% gain.

The development of the T-SPOT A201 platform is expected to strengthen Revvity’s infectious disease diagnostics and laboratory automation portfolio. By addressing the growing need for high-throughput latent TB testing, the company can enhance its position among large clinical laboratories while expanding opportunities within public health and diagnostic markets. Upon successful commercialization, the platform could drive broader adoption of Revvity’s automation solutions, support long-term customer relationships and contribute to sustained revenue growth.

RVTY currently has a market capitalization of $12.33 billion.

Image Source: Zacks Investment Research

More on the NewsThe T-SPOT A201 expands Revvity’s portfolio of automation solutions that simplify the T-SPOT.TB workflow without compromising clinical performance. The company already offers the FDA-approved and CE-IVD-marked Auto-Pure 2400 liquid handler for laboratories with lower testing volumes. Designed to process up to 24 samples per run, the Auto-Pure 2400 completes first-day T-SPOT.TB workflows in less than 3.5 hours with minimal user interaction while delivering low indeterminate results, high sensitivity and specificity, extended sample stability and efficient sample handling. These capabilities enable laboratories of different sizes to improve workflow efficiency while maintaining confidence in latent TB test results.

Built on the success of the Auto-Pure 2400 liquid handling platform, the T-SPOT A201 is designed to process up to 384 samples per instrument during an eight-hour shift while requiring only 45 seconds of hands-on time per sample. The platform is expected to help laboratories manage rising testing volumes driven by immigration screening, pre-treatment evaluations for immunosuppressive therapies and broader public health initiatives, while supporting timely and accurate latent TB detection.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the U.S. tuberculosis diagnostics market is predicted to be valued at $607.5 million in 2026 and is expected to witness a CAGR of 5.3% through 2035.

Factors like the increasing adoption of rapid molecular and nucleic acid amplification tests, growing focus on detection of latent and drug-resistant tuberculosis, rising emphasis on automation, digital reporting and laboratory workflow efficiency and continued reliance on government funding and public health laboratory networks for TB testing programs are boosting the market’s growth.

Other NewsRevvity recently announced the launch of Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research. It is scheduled to launch across the United States, Europe, the Middle East and the Africa region in late July 2026.

Revvity announced that its Signals Software business has been added to Anthropic’s directory for Model Context Protocol connectors, extending the capabilities of Signals AI beyond the Signals One platform. Through the integration, scientists can access Signals AI and connected R&D knowledge using Claude, including Claude Science, Anthropic’s AI workbench for scientific research.

RVTY’s Zacks Rank & Key PicksRevvity currently carries a Zacks Rank #5 (Strong Sell).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.

McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.